Delivery Order SPE2DB20D2104-SPE2DB25FNBFR

The Defense Logistics Agency awarded a $11,830 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of SKYRIZI 180 MG/1.2 ML on-body injectors with a completion deadline of October 15, 2025. SKYRIZI is a biologic medication used in the treatment of immune-mediated inflammatory diseases. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal medical procurement requirements. Performance will be executed at the company's corporate headquarters in Conshohocken, Pennsylvania.

AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems under the Defense Health Agency and other government entities. The company's extensive federal contract portfolio demonstrates expertise in delivering a broad spectrum of pharmaceutical products, including specialty medications, vaccines, and medical supplies across multiple therapeutic domains. This delivery order exemplifies the type of specialized pharmaceutical procurement that AmerisourceBergen regularly fulfills through its DLA Troop Support relationship, enabling rapid supply of critical medications to support military healthcare operations.